Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1753466620926853 http://scihub22266oqcxt.onion/10.1177/1753466620926853 C7243039!7243039 !32436445     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32436445 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Ther+Adv+Respir+Dis 2020 ; 14 (ä): 1753466620926853 Nephropedia Template TP {{tp|p=32436445 |t=2020. Potential specific therapies in COVID-19 |pdf=|usr=}}{{32436445 }} gab.com Text Potential specific therapies in COVID-19 JO: Ther Adv Respir Dis http://www.kidney.de/pget.php?&tw=1&pmid=32436445 #FOAvip COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section. Twit Text FOAVip Potential specific therapies in COVID-19 ????Ther Adv Respir Dis http://www.kidney.de/pget.php?&tw=1&pmid=32436445 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32436445 #FOAvip English Wikipedia <ref>{{Cite pmid|32436445 }}</ref> Potential specific therapies in COVID-19 #MMPMID32436445 Gul MH ; Htun ZM ; Shaukat N ; Imran M ; Khan A Ther Adv Respir Dis 2020[Jan]; 14 (ä): 1753466620926853 PMID32436445 show ga COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section. |Antiviral Agents/adverse effects/therapeutic use [MESH] |COVID-19 [MESH] |Coronavirus Infections/*drug therapy [MESH] |Humans [MESH] |Pandemics [MESH] |Pneumonia, Viral/*drug therapy [MESH]Potential specific therapies in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing